PYXS241220C2500
- 0.07
- -0.07-50.00%
Pyxis Oncology Newsroom
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $7 to $10
Institutional Investors in Pyxis Oncology, Inc. (NASDAQ:PYXS) See US$130m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care
Pyxis Oncology Shares Slump After William Blair Downgrade
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
Pyxis Oncology Is Maintained at Outperform by RBC Capital
Market-Moving News for November 21st
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $10
Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Pyxis Oncology Analyst Ratings
William Blair Initiates Pyxis Oncology(PYXS.US) With Hold Rating
Biggest Stock Movers Thursday: NVDA, PANW, and More
Express News | Pyxis Oncology Inc : William Blair Cuts to Market Perform
Pyxis Oncology Stock Tanks 41% After It Reports Preliminary PYX-201 Clinical Phase 1 Data
Pyxis Oncology Reports Promising Phase 1 Trial Results
Express News | Pyxis Oncology Announces Favorable Preliminary Pyx-201 Clinical Phase 1 Part 1 Data
Daily options tracking | Cryptos concept stocks strengthen again before the market opens! MSTR's volatility has been rising for several days; amazon hits a historic high! Call options within the week have doubled their profits.
Claiming to be a "SpaceX competitor," Rocket Lab surged 28% after earnings, with options volume skyrocketing threefold month-on-month to 0.4 million contracts. Call options accounted for 76.5%, among which the call options expiring this Friday with a strike price of $20 were the most active, with a volume exceeding 0.02 million contracts, and several call options saw premiums increase by over 200%.
Stifel Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $10